Clinical Trial Update: Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating cyclophosphamide as the sole graft-versus-host disease prophylaxis after allogeneic stem cell transplantation has completed in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: University of Cologne | Conditions: Multiple Myeloma, Non-Hodgkin-Lymphoma | Phase 2 | Status: COMPLETED